Gilead (GILD) Gets EU Nod for Breast Cancer Drug, Trodelvy

The European Commission grants marketing authorization to Gilead’s (GILD) Trodelvy as a monotherapy for the second-line treatment of adults with metastatic triple-negative breast cancer.